Nasdaq
$6.59▲ 2.09%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $46.6MShares out 7.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
50- 5d agoPre-market26.10.20 20:008-KKey event#●●●#●●●
Moleculin Biotech, Inc.
Moleculin Biotech (MBRX) will effect a 1-for-20 reverse stock split effective October 20, 2026. As a result, the number of outstanding shares will be reduced from approximately 20.91 million to approximately 1.05 million, and the stock will continue trading under the ticker 'MBRX' with a new CUSIP number.…more
$6.59+2.09%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.17Closed26.10.17 10:014Ownership
Moleculin Biotech, Inc.
Donald H. Picker, an insider at Moleculin Biotech, Inc., filed a Form 4 statement of changes in beneficial ownership on October 15, 2026. This filing formalizes the changes in the insider's stock holdings.…more
$6.59+2.09%vs prev closeView filingShare - 10.17Closed26.10.17 10:004Ownership
Moleculin Biotech, Inc.
Insider Walter V. Klemp of Moleculin Biotech, Inc. reported a change in beneficial ownership of company securities effective October 15, 2026. This filing is a Form 4 statement detailing the insider's updated holdings.…more
$6.59+2.09%vs prev closeView filingShare
49 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoPre-market26.10.20 21:12#●●●#●●●
Moleculin Biotech Provides Update on Annamycin Clinical Trial Progress
Moleculin Biotech shared progress on its Phase 2/3 MIRACLE trial for Annamycin in treating acute myeloid leukemia. While the company highlighted encouraging interim results, it noted that significant additional financing is required to continue its clinical programs.…more
$6.59+2.09%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.16Pre-market26.10.16 22:20
●●●●●●●● ●●●●● ●●●●●●
Moleculin Biotech will implement a 1-for-20 reverse stock split to consolidate its outstanding shares. This action is typically taken to boost share price and maintain compliance with Nasdaq listing requirements.…more
$6.59+2.09%vs prev close - 10.7Pre-market26.10.07 21:45
●●●●●●●● ●●●●● ●●●●●●
Moleculin Biotech will present updates on its oncology pipeline, including the Annamycin clinical program, at the upcoming 2026 Maxim Growth Summit. As this is an investor conference presentation rather than a new clinical milestone, the event is expected to have a neutral impact on the stock.…more
$6.59+2.09%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report